BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Gamaleya Center develops Delta and Omicron-adapted Sputnik V vaccine

23 August 2022 | News

The new version is also addressing the L-452-R mutation in Omicron BA5 variant which was not present in the BA1 variant



The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund (RDIF) have announced the development of the Sputnik V vaccine specifically adapted against Delta and Omicron variants of coronavirus.

The new version of Sputnik V has been Delta- and Omicron-adapted as Omicron is currently the dominant variant around the globe. This new version is also addressing the L-452-R mutation in Omicron BA5 variant which was not present in the BA1 variant.

The Delta and Omicron-adapted version of Sputnik V is the most promising version of the vaccine specifically adapted to new variants as compared to those tailored against the combination of the original strain and Omicron variant.

The Sputnik V vaccine adapted against the Delta and Omicron variants provides for a significant reduction in the viral load in the lungs of animals infected with the Omicron BA5 variant.